KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Teva Pharmaceutical Industries (TEVA) Operating Margin (2016 - 2026)

Teva Pharmaceutical Industries (TEVA) has disclosed Operating Margin for 11 consecutive years, with 16.37% as the latest value for Q1 2026.

  • For Q1 2026, Operating Margin rose 304.0% year-over-year to 16.37%; the TTM value through Mar 2026 reached 13.19%, up 1035.0%, while the annual FY2025 figure was 12.5%, 1433.0% up from the prior year.
  • Operating Margin hit 16.37% in Q1 2026 for Teva Pharmaceutical Industries, up from 6.37% in the prior quarter.
  • Across five years, Operating Margin topped out at 19.69% in Q3 2025 and bottomed at 25.54% in Q2 2022.
  • Average Operating Margin over 5 years is 0.58%, with a median of 0.12% recorded in 2024.
  • Year-over-year, Operating Margin crashed -4043bps in 2022 and then skyrocketed 4116bps in 2023.
  • Teva Pharmaceutical Industries' Operating Margin stood at 24.2% in 2022, then surged by 170bps to 16.96% in 2023, then crashed by -106bps to 1.0% in 2024, then surged by 737bps to 6.37% in 2025, then surged by 157bps to 16.37% in 2026.
  • According to Business Quant data, Operating Margin over the past three periods came in at 16.37%, 6.37%, and 19.69% for Q1 2026, Q4 2025, and Q3 2025 respectively.